INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
INmune Bio Inc. - Common stock (INMB)
Company Research
Source: GlobeNewswire
BOCA RATON, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company focused on developing therapies that harness the patient’s innate immune system, today announces new preclinical data for INB03 (XPro1595 for oncology). The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego on April 17-22. The poster, titled, “Soluble TNF blockade overcomes tyrosine kinase inhibitors resistance in HER2-positive breast cancer,” details how INB03 (“XPro™”), a first-in-class dominant-negative soluble TNF (sTNF) inhibitor, significantly enhances the anti-tumor activity of the tyrosine kinase inhibitors (TKIs) lapatinib and tucatinib while reducing metastatic spread to the brain, lungs, and liver in HER2-positive breast cancer models. It was authored by collaborators from the Instituto de Biología y Medicina Experimental (IBYME-CONICET) in Buenos Aires, Argentina. Key
Show less
Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INMB alerts
High impacting INmune Bio Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
INMB
News
- INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]Yahoo! Finance
- INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- INmune Bio Inc. Announces 2025 Results and Provides Business UpdateGlobeNewswire
- INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.GlobeNewswire
INMB
Earnings
- 10/30/25 - Beat
INMB
Sec Filings
- 3/30/26 - Form 10-K
- 2/27/26 - Form 8-K
- 2/23/26 - Form 8-K
- INMB's page on the SEC website